Immunotherapy Archives

News and Trends 23 Jan 2017

French Biotech partners with Merck to Fight Tumor Resistance

Domain Therapeutics and Merck have partnered up to develop immuno-oncology drug candidates that can boost the performance of checkpoint inhibitors. Domain Therapeutics has entered a collaboration and licensing agreement with German Merck in immuno-oncology. The big pharma is offering over €240M in milestones and will support research activities in exchange for worldwide rights to new drug candidates targeting […]

January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 23 Jan 2017

“Senior Staff Snobbery separates Academia from the Biotech Industry”

We caught up with Mark Lowdell, Director of Cellular Therapeutics and the RFH/UCL Cancer Biobank. As one of the few successful scientist-entrepreneurs, he has some ideas about bridging academia and industry in biomedicine. Mark Lowdell was introduced to me by his business partner, RJ Tesi. Tesi co-founded INmune Bio, a promising California-based startup, on Lowdell’s […]

January 23, 2017 - 6 minutesmins - By Evelyn Warner

Screenshot 2017 01 12 at 6.46.14 PM 1 e1484300509836

Startup Scout 13 Jan 2017

The Good, the Bad and the Cancer-Fighting Macrophage

We decided to stick around England this week and made a short trip from London to visit the young biotech Macrophage Pharma. The company is developing immuno-oncology technology that could turn ‘bad’ tumor-associated macrophages into ‘good’, cancer-fighting cells. City: Berkhamsted, UK (near London) Founded: 2014 Employees: 1-10 Financial data: €10.38M total raised Mission: Macrophage Pharma develops next-generation immunotherapies […]

January 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 11 Jan 2017

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

Merck is diversifying its oncology portfolio with four new programs licensed from Vertex Pharmaceuticals, including multiple DNA damage and repair drugs. Merck has entered a licensing agreement with Boston-based Vertex Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional […]

January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jan 2017

Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors

Servier has signed a deal that could give it access to up to eight bispecific drug candidates with immuno-oncology applications from Pieris Pharmaceuticals. Servier, one of France’s biggest pharma companies, is offering up to €1.7B to US-based Pieris Pharmaceuticals. The team will initially develop five programs that can be later expanded to up to eight. For […]

January 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2017

New German Immuno-oncology Partnership takes on Solid Tumors

TCR2 Therapeutics is initiating a partnership with academia to boost its TCR technology with the aim of overcoming the huge challenges of treating solid tumors. TCR2 Therapeutics, a Boston immuno-oncology startup launched in 2015 and funded by the Munich biotech mafia, is starting the year with a multi-year collaboration with the University Hospital of Ludwig-Maximilians-University (LMU) in, […]

January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 3 Jan 2017

10 Hot European Biotechs to Observe in 2017 🚀

New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […]

January 3, 2017 - 5 minutesmins - By Philip Hemme

Interview 2 Jan 2017

The Story behind one of the Most Successful Danish Biotech Entrepreneurs

The series of profiles on impressive biotech leaders continues: John Haurum founded one of the most successful biotech companies in Denmark and is now leading one of the hottest European immuno-oncology companies. Here are some of his lessons and thoughts looking back at his rich career. John Haurum, born in Denmark, studied medicine at Aarhus University […]

January 2, 2017 - 6 minutesmins - By Philip Hemme

News and Trends 22 Dec 2016

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […]

December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […]

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2016

These are our 10 Most Read Biotech Articles of 2016

From the hottest research areas to the most popular city for biotech, which biotech articles have managed to hook our readers the most this year? After an exciting journey of 2 years, Labiotech.eu is now the leading biotech media in Europe, with over 50k monthly readers. To celebrate the end of another amazing year, we wanted […]

December 20, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Dec 2016

Young Immuno-Oncology Biotechs attract Funding to Cure Metastasis

Amcure and TILT Biotherapeutics announced yesterday new financing rounds supporting the development of unique strategies to cure cancer metastasis. Amcure, in Germany, is fighting highly metastatic forms of cancer by targeting angiogenesis. The company just closed a Series B round with a total of €6M from already existing investors. With the funds, Amcure plans to accelerate […]

December 16, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

French Biotech partners with Merck to Fight Tumor Resistance

“Senior Staff Snobbery separates Academia from the Biotech Industry”

The Good, the Bad and the Cancer-Fighting Macrophage

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors

New German Immuno-oncology Partnership takes on Solid Tumors

10 Hot European Biotechs to Observe in 2017 🚀

The Story behind one of the Most Successful Danish Biotech Entrepreneurs

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

These are our 10 Most Read Biotech Articles of 2016

Young Immuno-Oncology Biotechs attract Funding to Cure Metastasis

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!